Purchase this article with an account.
Pavel Iserovich; Evaluation of pharmacological approaches to downregulation of pathogenic gliotic response in the eye. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1429.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Reactive gliosis is a sequela of many neurodegenerative conditions. Gliotic response in Muller cells and in retinal and optic nerve astrocytes may contribute to pathogenesis of many eye disorders including glaucoma, AMD, DR, retinal detachment and traumatic optic neuropathy. Insult-induced swelling of glial cells could be a significant factor in pathogenesis of these conditions. Prevention of injury-induced edema by inhibiting glial cell swelling may be a common strategy for pharmacological intervention in neurodegenerative diseases of the eye. We work on evaluation of the group of fluorenone compounds as a potential treatment for attenuation of reactive gliosis in the eye
Label-free dynamic mass redistribution technology along with the calcein fluorescence quenching approach were used for assessing the ability of test compounds to attenuate stress-induced swelling in the human SBN-19 astrocytic cell line.
We found that the prototypic fluorenone compound reduces stress-induced swelling in cultured SBN-19 cells with a distinct but complicated dose-dependent pattern. The maximal inhibition of swelling was observed in the nanomolar range of compound concentrations
Our in vitro efficacy data correlates well with the previously reported results on the effect of test compound on inhibition of pathogenic swelling in brain slices. Dynamic mass redistribution and calcein fluorescence quenching technologies seems to be adequate for assessing in vitro efficacy of test compounds.
This PDF is available to Subscribers Only